TNFRSF9 and neoplasm: For example, clinical trials of GEN1046 (bispecific antibodies PD‐L1 × CD137, BioNTech, Mainz, Rheinland‐Pfalz, Germany) show potent anti‐tumor activity in vivo superior to PD‐L1 blockade monotherapy and significant early clinical activity across different dose levels in the population resistant to prior immunotherapy or typically less sensitive to an immune checkpoint inhibitor in Phase I/IIa clinical trials; expectedly, a good safety also is observed [49].